# US 8,277,807 B2 · Pharmaceutical combinations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,807 B2
- Document ID: US8277807B2
- Status: Granted
- Kind: B2
- Application number: 12/445,141
- Filed: 2007-10-12
- Published: 2010-04-15
- Granted: 2012-10-02
- Earliest claimed: 2006-10-12
- Assignees: Astex Therapeutics Limited
- Inventors: Neil James Gallagher; John Francis Lyons; Neil Thomas Thompson; Stephen Murray Yule; Christopher William Murray
- Web page: https://patentgrep.com/patent/US8277807B2

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides combinations comprising (or consisting essentially of) one or more ancillary compound(s) and a compound of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group —(O)n—R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The combinations have activity as Hsp90 inhibitors.

## Claims

### Claim 1

A combination comprising one or more ancillary compound(s) and a compound of the formula (VI):
or a salt, solvate, tautomer or N-oxide thereof;
wherein the bicyclic group:
is selected from the structures Cl, C5 and C6:
wherein n is 0, 1, 2 or 3;
R1 is hydroxy or hydrogen;
R2a is hydroxy or methoxy provided that at least one of R1 and R2a is hydroxy;
R3 is selected from cyano; C1-5 hydrocarbyl and C1-5 hydrocarbyloxy; wherein the C1-5 hydrocarbyl and C1-5 hydrocarbyloxy moieties are each optionally substituted by one or more substituents selected from hydroxy, halogen, C1-2 alkoxy, amino, mono- and di-C1-2 alkylamino, and aryl and heteroaryl groups of 5 to 12 ring members;
R4a is selected from hydrogen, fluorine, chlorine and methoxy;
R8 is selected from hydrogen and fluorine; and
R10 is selected from:
halogen;
hydroxy;
trifluoromethyl;
cyano;
nitro;
carboxy;
amino;
mono- or di-C1-4 hydrocarbylamino;
carbocyclic and heterocyclic groups having from 3 to 12 ring members; and
a group Ra—Rb; wherein:
Ra is a bond, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2; and
Rb is selected from hydrogen; carbocyclic and heterocyclic groups having from 3 to 12 ring members; and C1-12 hydrocarbyl optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C1-8 non-aromatic hydrocarbylamino, and carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-12 hydrocarbyl group may optionally be replaced by O, S, SO, SO2, NRc, X1C(X2), C(X2)X1 or X1C(X2)X1;
Rc is selected from Rb, hydrogen and C1-4 hydrocarbyl; and
X1 is O, S or NRc and X2 is ═O, ═S or ═NRc,
wherein the one or more ancillary compound(s) is selected from the group consisting of:
I. corticosteroids, antiandrogens, antiestrogens, aromatase inhibitors and GNRAs;
II. interferons and interleukins;
III. tretinoin, alitretinoin and bexarotene;
IV. rituximab, tositumomab and gemtuzumab ozogamicin; alemtuzumab, alemtuzumab, and bevacizumab;
V. camptothecin compounds;
VI. 5-fluorouracil, capecitabine, gemcitabine, cytarabine, fludarabine, raltitrexed, pemetrexed and methotrexate;
VII. vinca alkaloids;
VIII. taxanes;
IX. epothilones;
X. platinum compounds;
XI. anthracycline derivatives, mitoxantrone and podophyllotoxin derivatives;
XII. aziridines, nitrogen mustards, nitrosurea alkylating agents and bisalkanesulfonates;
XIII. CDK inhibitors;
XIV. COX-2 inhibitors;
XV. trichostatin A, suberoylanilide hydroxamic acid, JNJ-16241199, LAQ-824, MGCD-0103, PXD-101;
XVI. selective immunoresponse modulators;
XVII. temozolomide, decitabine, 5-azacitidine, pseudoisocytidine and 5-fluoro-2′-deoxycytidine;
XVIII. bortezimib and bleomycin;
XIX. aurora inhibitors;
XX. herbimycin, geldanamycin, 17-AAG, 17-DMAG, CNF-2024, and IPI-504;
XXI. checkpoint targeting agents;
XXII. DNA repair inhibitors;
XXIII. inhibitors of G-protein coupled receptor inhibitors;
XXIV. trastuzumab, cetuximab, panitumumab, tipifamib, gefitinib, erlotinib, bevacizumab, sunitinib, imatinib mesylate, sorafenib dasatinib, lapatinib, nilotinib, vandetanib, vatalinib and CHIR-258 and
XXV. anti-emetic agents, agents that prevent or decrease the duration of chemotherapy associated neutropenia and prevent complications that arise from reduced levels of red blood cells or white blood cells, agents that inhibit bone resorption, bisphosphonate agents, agents that suppress inflammatory responses, agents that reduce blood levels of growth hormone and IGF-I in acromegaly patients, antidotes to drugs that decrease levels of folic acid, and agents for the treatment of oedema and thromoembolic episodes.

### Claim 2 (depends on 1)

A combination according to claim 1 wherein R1 and R2a are both hydroxy.

### Claim 3 (depends on 1)

A combination according to claim 1 wherein R3 is selected from isopropyl and tert-butyl.

### Claim 4 (depends on 1)

A combination according to claim 1 wherein R4a is hydrogen and R8 is hydrogen.

### Claim 5 (depends on 1)

A combination according to claim 1 wherein the compound of the formula (VI) is a compound of the formula (VIIa):
wherein R3 is selected from C1-5 alkyl, C2-5 alkenyl and C3-4 cycloalkyl groups; R4a is selected from hydrogen, fluorine, chlorine and methoxy; R8 is hydrogen or fluorine; n is 0, 1 2 or 3;
R10 is selected from halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, mono- or di-C1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group Ra—Rb wherein Ra is a bond, O, CO, X1C(X2), C(X2)X1, X1C(X2)X1, S, SO, SO2, NRc, SO2NRc or NRcSO2; and Rb is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C1-12 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, carboxy, amino, mono- or di-C1-8 non-aromatic hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C1-12 hydrocarbyl group may optionally be replaced by O, S, SO, SO2, NRc, X1C(X2), C(X2)X1, or X1C(X2)X1;
Rc is selected from Rb, hydrogen and C1-4 hydrocarbyl; and
X1 is O, S or NRc and X2 is ═O, ═S or ═NRc.

### Claim 6 (depends on 5)

A combination according to claim 5 wherein the compound of the formula (VIIa) is a compound of formula (VIIb):
wherein R3 is selected from C1-5 alkyl, C2-5 alkenyl and C3-4 cycloalkyl groups; R4a is selected from hydrogen, fluorine, chlorine and methoxy; R8 is hydrogen or fluorine; n is 0, 1 2 or 3; and R10cc is selected from:
halogen;
CO2R14 wherein R14 is hydrogen or C1-6 alkyl;
C1-4 alkyl optionally substituted by hydroxy or C1-2 alkoxy;
C1-4 alkoxy optionally substituted by hydroxy or C1-2 alkoxy; or
a group [sol], CH2[sol], C(O)[sol], OCH2CH2[sol] or OCH2CH2CH2[sol] where [sol] is selected from the following groups
wherein X4 is NH or O, m is 0 or 1, n is 1, 2 or 3, R11 is hydrogen, COR12, C(O)OR12 or R12; R12 is C1-6 alkyl, C3-6 cycloalkyl, aryl, aryl-C1-6 alkyl or CH2R15; and R15 is selected from hydrogen, C1-6 alkyl, C3-6 cycloalkyl, hydroxy-C1-6 alkyl, piperidine, N—C1-6 alkylpiperazine, piperazine, morpholine, COR13 or C(O)OR13; and R13 is C1-6 alkyl.

### Claim 7 (depends on 1)

A combination according to claim 1 wherein the compound of formula (VI) is:
(3-tert-butyl-4-hydroxy-phenyl)-(2,3-dihydro-indol-1-yl)-methanone;
(1,3-dihydro-isoindol-2-yl)-(2,4-dihydroxy-5-isopropyl-phenyl)-methanone;
(3-tert-butyl-4-hydroxy-phenyl)-(1,3-dihydro-isoindol-2-yl)-methanone;
(1,3-dihydro-isoindol-2-yl)-(4-hydroxy-3-isopropyl-phenyl)-methanone;
(1,3-dihydro-isoindol-2-yl)-(5-ethyl-2,4-dihydroxy-phenyl)-methanone;
(5-cyclopropyl-2,4-dihydroxy-phenyl)-(1,3-dihydro-isoindol-2-yl)-methanone;
(5-sec-butyl-2,4-dihydroxy-phenyl)-(1,3-dihydro-isoindol-2-yl)-methanone;
(5-chloro-1,3-dihydro-isoindol-2-yl)-(2,4-dihydroxy-5-isopropyl-phenyl)-methanone;
[5-(3-amino-propoxy)-1,3-dihydro-isoindol-2-yl]-(2,4-dihydroxy-5-isopropyl-phenyl)methanone;
(1,3-Dihydro-isoindol-2-yl)-(2,4-dihydroxy-5-trifluoromethyl-phenyl)-methanone;
(2,4-Dihydroxy-5-isopropyl-phenyl)-{4-[2-(2-methoxy-ethoxy)-ethoxy]-1,3-dihydroisoindol-2-yl}methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[4-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[4-(3-morpholin-4-yl-propoxy)-1,3-dihydroisoindol-2-yl]methanone;
(3-sec-Butyl-4-hydroxy-phenyl)-(1,3-dihydro-isoindol-2-yl)-methanone;
(5-tert-Butyl-2,4-dihydroxy-phenyl)-(1,3-dihydro-isoindol-2-yl)-methanone;
(1,3-Dihydro-isoindol-2-yl)-(2-hydroxy-5-isopropyl-4-methoxy-phenyl)-methanone;
(4,7-difluoro-1,3-dihydro-isoindol-2-yl)-(2,4-dihydroxy-5-isopropyl-phenyl)-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-(5-fluoro-1,3-dihydro-isoindol-2-yl)-methanone;
(1,3-dihydro-isoindol-2-yl)-(3-fluoro-2,4-dihydroxy-5-isopropyl-phenyl)-methanone;
(1,3-dihydro-isoindol-2-yl)-(2-fluoro-4,6-dihydroxy-3-isopropyl-phenyl)-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-(4-fluoro-1,3-dihydro-isoindol-2-yl)-methanone hydrochloride;
(5-chloro-6-methoxy-1,3-dihydro-iso-indol-2-yl)-(2,4-dihydroxy-5-isopropyl-phenyl)methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(2-methoxy-ethoxy)-1,3-dihydro-isoindol-2-yl]methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(3-morpholin-4-yl-propoxy)-1,3-dihydroisoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone;
(5-amino-1,3-dihydro-isoindol-2-yl)-(2,4-dihydroxy-5-isopropyl-phenyl)-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-(5-methoxy-1,3-dihydro-isoindol-2-yl)-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-(5-morpholin-4-yl-1,3-dihydro-isoindol-2-yl)-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-yl)-1,3-dihydro-isoindol-2-yl]-methanone;
2-(2,4-dihydroxy-5-isopropyl-benzoyl)-2,3-dihydro-1H-isoindole-5-carboxylic acid methyl ester;
2-(2,4-dihydroxy-5-isopropyl-benzoyl)-2,3-dihydro-1H-isoindole-5-carboxylic acid;
(2,4-dihydroxy-5-isopropyl-phenyl)-(5-morpholin-4-ylmethyl-1,3-dihydro-isoindol-2-yl)methanone;
{3-[2-(2,4-dihydroxy-5-isopropyl-benzoyl)-2,3-dihydro-1H-isoindol-5-yloxy]-propyl}carbamic acid tert-butyl ester;
(2,4-dihydroxy-5-isopropyl-phenyl)-(5-methyl-1,3-dihydro-isoindol-2-yl)-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(2-isopropylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone;
N-{2-[2,4-dihydroxy-5-isopropyl-benzoyl)-2,3-dihydro-1H-isoindol-5-yloxy]-ethyl}-2-morpholin-4-yl-acetamide;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-hydroxy-1-methyl-piperidin-4-yl)-1,3-dihydroisoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-{5-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-1,3-dihydro-isoindol-2-yl}-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-piperazin-1-yl-phenyl)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(1-dimethylamino-2-hydroxy-ethyl)-1,3-dihydroisoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-1-hydroxy-ethyl)-1,3-dihydroisoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(piperazine-1-carbonyl)-1,3-dihydro-isoindol-2-yl]-methanone hydrochloride;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[4-(3-morpholin-4-yl-propoxy)-1,3-dihydroisoindol-2-yl]methanone;
[5-(2-amino-ethoxy)-1,3-dihydro-isoindol-2-yl]-(2,4-dihydroxy-5-isopropyl-phenyl)methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-(5-hydroxy-1,3-dihydro-isoindol-2-yl)-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-{5-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-1,3dihydro-isoindol-2-yl}-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-morpholin-4-yl-piperidin-1-yl)-1,3-dihydroisoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(1-methyl-piperidin-4-ylamino)-1,3-dihydroisoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-isopropyl-piperazin-1-yl)-1,3-dihydroisoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-(5-piperazin-1-yl-1,3-dihydro-isoindol-2-yl)methanone;
4-[2-(2,4-Dihydroxy-5-isopropyl-benzoyl)-2,3-dihydro-1H-isoindol-5-ylamino]piperidine-1-carboxylic acid tert-butyl ester;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(piperidin-4-ylamino)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[4-(4-methyl-piperazin-1-yl)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[4-(piperidin-4-ylamino)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-(5-dimethylaminomethyl-1,3-dihydro-isoindol-2-yl)methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazine-1-carbonyl)-1,3-dihydro-isoindol-2-yl]-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-{5-[2-(2,2-dimethyl-propylamino)-ethoxy]-1,3-dihydro-isoindol-2-yl}-methanone;
[5-(2-cyclopentylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-(2,4-dihydroxy-5-isopropylphenyl)-methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-(5-piperidin-1-ylmethyl-1,3-dihydro-isoindol-2-yl)methanone;
(2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(4-hydroxypiperidin-4-yl)-1,3-dihydro-isoindol-2-yl]-methanone;
(5-chloro-6-hydroxy-1,3-dihydro-isoindol-2-yl)-(2,4-dihydroxy-5-isopropyl-phenyl)methanone;
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-yl)-1,3-dihydro-isoindol-2-yl]-methanone; or
(2,4-dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-7-methyl-1,3-dihydroisoindol-2-yl]-methanone;
or salts, solvates, N-oxides and tautomers thereof.

### Claim 8 (depends on 1)

A combination according to claim 1 wherein the ancillary compound and compound of formula (VI) are:
(a) physically associated; or
(b) in admixture; or
(c) chemically or physicochemically linked; or
(d) chemically or physicochemically co-packaged; or
(e) unmixed but co-packaged or co-presented.

### Claim 9 (depends on 1)

The combination according to claim 1 wherein the compound of formula (VI) is the L-lactate salt of (2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindol-2-yl]-methanone.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising a combination according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for:
the inhibition or treatment of a disease state or condition mediated by Hsp90, which method comprises administering to a subject in need thereof a combination as defined in anyone of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or
alleviating or reducing the incidence of a disease state or condition mediated by Hsp90, which method comprises administering to a subject in need thereof a combination as defined in anyone of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or
inhibiting Hsp90, which method comprises contacting the Hsp90 with an Hsp90-inhibiting combination as defined in anyone of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for:
treating a disease or condition comprising or arising from abnormal cell growth in a mammal, which method comprises administering to a subject in need thereof a combination as defined in anyone of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 in an amount to inhibit abnormal cell growth; or
alleviating or reducing the incidence of a disease or condition comprising or arising from abnormal cell growth in a mammal, which method comprises administering to the mammal a combination as defined in anyone of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 in an amount to inhibit abnormal cell growth; or
the inhibition or treatment of a proliferative disorders selected from a carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, gastrointestinal system, or skin; a hematopoieitic tumour of lymphoid lineage; a hematopoietic tumor of myeloid lineage; thyroid follicular cancer; a tumor of mesenchymal origin; a tumor of the central or peripheral nervous system; melanoma; seminoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoacanthoma; thyroid follicular cancer; or Kaposi's sarcoma which method comprises administering to a subject in need thereof a combination as defined in any one of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or
alleviating or reducing the incidence of a proliferative disorders selected from a carcinoma of the bladder, breast, colon, kidney, epidermis, liver, lung, esophagus, gall bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, gastrointestinal system, or skin; a hematopoietic tumor of lymphoid lineage; a hematopoietic tumor of myeloid lineage; thyroid follicular cancer; a tumour of mesenchymal origin; a tumor of the central or peripheral nervous system; melanoma; semmoma; teratocarcinoma; osteosarcoma; xeroderma pigmentosum; keratoacanthoma; thyroid follicular cancer; or Kaposi's sarcoma which method comprises administering to a subject in need thereof a combination as defined in anyone of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or
the treatment of a cancer which method comprises administering to a subject in need thereof a combination as defined in anyone of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, which method is characterized by the absence of drug resistance.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method of modulating a cellular process by inhibiting the activity of Hsp90 using a combination according to anyone of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method:
for the inhibition or treatment of a viral infection, which method comprises administering to a subject in need thereof a combination according to anyone of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or
for blocking or inhibiting viral replication in a host organism, which method comprises administering to the host organism a combination according to anyone of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

### Claim 15 (depends on 1, 5, 6)

A method for:
the inhibition or treatment of a disease state or condition mediated by Hsp90 which method comprises administering to the subject a compound of the formula (VI) according to claim 1, (VIIa) according to claim 5 or (VIIb) according to claim 6 in a subject which is undergoing treatment with one or more ancillary compounds; or
the inhibition or treatment of a disease state or condition comprising or arising from abnormal cell growth in a mammal which method comprises administering to the subject a compound of the formula (VI) according to claim 1, (VIIa) according to claim 5 or (VIIb) according to claim 6 in a subject which is undergoing treatment with one or more ancillary compounds; or
treating a disease or condition comprising or arising from abnormal cell growth in a mammal, which method comprises administering to the mammal a compound of the formula (VI) according to claim 1, (VIIa) according to claim 5 or (VIIb) according to claim 6 in an amount effective in inhibiting abnormal cell growth, wherein the mammal is undergoing treatment with one or more ancillary compounds; or
alleviating or reducing the incidence of a disease or condition comprising or arising from abnormal cell growth in a mammal, which method comprises administering to the mammal a compound of the formula (VI) according to claim 1, (VIIa) according to claim 5 or (VIIb) according to claim 6 in an amount effective in inhibiting abnormal cell growth, wherein the mammal is undergoing treatment with one or more ancillary compounds.

### Claim 16 (depends on 1, 5, 6)

A method for (i) sensitizing malignant cells to one or more ancillary compounds; (ii) alleviating or reducing the incidence of resistance to one or more ancillary compounds; (iii) reversing resistance to the one or more ancillary compounds of claim 1; (iv) potentiating the activity of the one or more ancillary compounds of claim 1; (v) delaying or inhibiting the onset of resistance to the one or more ancillary compounds of claim 1, which method comprises administering to a subject undergoing treatment with said ancillary compound a compound of the formula (VI) according to claim 1, (VIIa) according to claim 5 or (VIIb) according to claim 6.

### Claim 17 (depends on 1)

The combination of claim 1, wherein the ancillary compound is selected from the group consisting of:
I. tamoxifen; toremifene; raloxifene; medroxyprogesterone; megestrol/megestrel; aminoglutethimide; letrozole; anastrozole; exemestane; goserelin; leuprolide; abarelix; fluoxymestrone; diethylstilbestrol; ketoconazole; fulvestrant; flutamide; bicalutimide; nilutamide; cyproterone and buserelin,
II. interferon α-2b, interferon α-2a, Proleukin® IL-2, Picibanil, Romurtide, Sizofuran, Virulizin and Thymosin alpha 1;
III. tretinoin, alitretinoin and bexarotene;
IV. rituximab, tositumomab and gemtuzumab ozogamicin; alemtuzumab, alemtuzumab, and bevacizumab;
V. irinotecan and topotecan;
VI. 5-fluorouracil, capecitabine, gemcitabine, cytarabine, fludarabine, raltitrexed, pemetrexed and methotrexate;
VII. vindesine, vinvesir, vinblastine, vincristine and vinorelbine;
VIII. paclitaxel, docetaxel;
IX. ixabepilone, patupilone, BMS-247550 and desoxyeopthilone;
X. cisplatin, carboplatin and oxaliplatinchloro(diethylenediamino)-platinum (II) chloride; dichloro(ethylenediamino)-platinum (II); spiroplatin; iproplatin; diamino(2-ethylmalonato)platinum (II); (1,2-diaminocyclohexane)malonatoplatinum (II); (4-carboxyphthalo)-(1,2-diaminocyclohexane)platinum (II); (1,2-diaminocyclohexane)(isocitrato)platinum (II); (1,2-diaminocyclohexane)-cis-(pyruvato)platinum (II); onnaplatin; and tetraplatin;
XI. anthracycline derivatives, mitoxantrone and podophyllotoxin derivatives;
XII. cyclophosphamide, ifosfamide/ifosphamide, chlorambucil, carmustine and lomustine, mitomycin, busulfan, estramustine, mechlorethamine, melphalan, bischloroethylnitrosurea, cyclohexylchloroethylnitrosurea, methylcyclohexylchloroethylnitrosurea, nimustine, procarbazine, dacarbazine, temozolimide and thiotepa;
XIII. seliciclib, alvocidib, 7-hydroxy-staurosporine, PHA533533 and PD332991;
XIV. celecoxib, arcoxia and lumiracoxib;
XV. trichostatin A, suberoylanilide hydroxamic acid, PXD-101;
XVI. lenalidomide and thalidomide;
XVII. temozolomide, decitabine, 5-azacitidine, pseudoisocytidine and 5-fluoro-2′-deoxycytidine;
XVIII. bortezimib and bleomycin;
XIX. PHA-739358;
XX. IPI-504;
XXI. bendamustine, BSI-201 and AG-014699;
XXII. atrasentan;
XXIII. trastuzumab, cetuximab, panitumumab, tipifarnib, gefitinib, erlotinib, bevacizumab, sunitinib, imatinib mesylate, sorafenib dasatinib, lapatinib, nilotinib, vandetanib, vatalinib and CHIR-258 and
XXIV. erythropoietin, granulocyte macrophage-colony stimulating factor, granulocyte colony stimulating factor, zoledronate, pamidronate, ibandronate, dexamethazone, prednisone, prednisolone, octreotide acetate, leucovorin, folinic acid and megestrol acetate.

### Claim 18 (depends on 1)

The combination of claim 1, wherein the ancillary compound is selected from the group consisting of:
Paclitaxel
Cisplatin
Dacarbazine
Erlotinib
Imatinib
Sunitinib
Nilotinib
Trastuzumab
Bortezomib
Gemcitabine
Cytarabine
Decitabine
Docetaxel
5-fluorouracil
lapatinib
letrozole and
tamoxifen.

### Claim 19 (depends on 18)

The combination of claim 18, wherein the ancillary compound is selected from the group consisting of
Paclitaxel
Cisplatin
Dacarbazine
Erlotinib
Imatinib
Sunitinib and
Nilotinib.

### Claim 20 (depends on 1)

The combination according to claim 1 wherein the compound of formula (VI) is (2,4-dihydroxy-5-isopropyl-phenyl)-[5-(4-methyl-piperazin-1-ylmethyl)-1,3-dihydro-isoindol-2-yl]-methanone.
